Migami negotiating buy of drug-delivery platform

Migami, a publicly-traded US pharmaceutical and cosmeceutical company, is negotiating a letter of intent regarding an asset purchase agreement  with respect to its proposed acquisition of a patented, liposomal  drug-delivery platform and certain related manufacturing assets. The  platform being acquired is considered by many to be the next  evolutionary step in liposomal technology, the company says.

This prospective purchase represents a vital component of Migami's  strategic efforts in acquiring proprietary, drug-delivery systems that  can be used to maximize the market potential for innovative,  cutting-edge drug-delivery systems, the company notes. This planned  purchase is the first in a series, which will provide Migami with a wide  array of such proprietary, drug-delivery systems to offer to its  customers, as well as manufacturing capability. Although Migami's  initial strategy emphasizes Asia, where it has an established network of  industry partners, the firm's ultimate plan is to expand its operations  to a worldwide basis.